Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer
Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer
Recruiting · NCT06815497 · Registry updated 2026-01-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Recruiting | Phase 2 | 2026-01-28 | NCT06815497 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Dartmouth-Hitchcock Medical Center | 104 |
| Tyler J Curiel | 2 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dartmouth Hitchcock | Lebanon | United States | 8 |
| Dartmouth-Hitchcock Manchester | Manchester | United States | 1 |